Towards Healthcare
GLP-1 Drugs Market Size to Lead USD 121.13 Bn by 2034

GLP-1 Drugs Market Trends 2025 AI Innovation, 83% Injectable Dominance and New Global Partnerships

According to market projections, the GLP-1 drugs sector is expected to grow from USD 48.3 billion in 2024 to USD 121.13 billion by 2034, reflecting a CAGR of 9.63%. The GLP-1 drugs market is expanding due to increasing incidences of type 2 diabetes as well as growing GLP-1 drug applications. North America led the market due to a rise in obesity and diabetes.

  • Last Updated: 26 September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

FAQ's

The GLP-1 drugs market in 2025 is valued at USD 52.95 billion and is projected to climb to USD 121.13 billion by 2034, with a CAGR of 9.63% over the forecast period.

North America is currently leading the GLP-1 drugs market due to a rise in obesity and diabetes.

The GLP-1 drugs market includes 5 segments such as by indication, by drug type brand, by route of administration, by end user, and by region.

Some key players include Novo Nordisk A S, Eli Lilly and Company, AstraZeneca plc, and Sanofi S.A.

Key trends include growth in online distribution of GLP-1 drugs and innovation in new drug candidates.

The GLP-1 drugs are a class of drugs that mimic the GLP-1 hormone to regulate blood sugar levels, enhance insulin secretion, and promote satiety.

The GLP-1drugs are used for the treatment of type 2 diabetes (T2D), obesity weight loss management, cardiovascular, and neurodegenerative diseases.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.